GeneIII Targets U.S. Consumers With Its L-Ergothioneine Supplement Line

GeneIII, a supplement brand built around L-Ergothioneine (EGT), is moving to expand its presence among U.S. consumers with a product line positioned in the longevity and healthy aging category. The company says it has served more than one million customers worldwide and holds more than 30 patents tied to its precision fermentation process, which it introduced in 2021 to manufacture EGT at 99.99% purity.

The company says it has invested more than $15 million in clinical studies on EGT and points to more than 100 peer-reviewed studies on the ingredient across the broader scientific literature. GeneIII manufactures the ingredient in-house through proprietary fermentation technology; products are encapsulated and bottled in the U.S. in GMP-compliant facilities, per the company. Its flagship GeneIII L-Ergothioneine capsule is priced from $49 and delivers a 30mg dose per serving. A second product, GeneIII L-EGT + Liver Support, rounds out the current lineup. The brand also offers free U.S. shipping and a 90-day money-back guarantee, per its site.

The company has received an FDA "No Questions" letter for its GRAS notification, per the company, and subjects each batch to third-party laboratory testing covering purity, identity, heavy metals and microbial safety. Research collaborations include Professor Barry Halliwell and Temasek Life Sciences Laboratory. Clinical trials have been registered with the WHO's International Clinical Trials Registry Platform.

Why it matters

EGT remains a relatively unfamiliar ingredient in the American supplement market compared with more established compounds in the longevity category, but GeneIII's U.S. push signals that science-forward, single-ingredient brands are betting on growing consumer appetite for novel longevity inputs. The brand's vertical integration model, producing its own raw material rather than sourcing from third-party suppliers, provides potential margin and quality-control advantages that become more meaningful as category competition intensifies. For the broader supplement industry, brands entering the longevity space with proprietary manufacturing and registered clinical trials are staking a credibility position that commodity-sourced finished-goods brands cannot easily replicate, and that positioning may matter more as the FDA pays closer attention to structure-function claims in the category.

What to watch

Whether GeneIII pursues retail distribution beyond a direct-to-consumer model will be the clearest indicator of how aggressively the company plans to scale in the U.S. A move into specialty or mass-market retail would test whether a less familiar ingredient name can drive shelf pull without the digital storytelling that supports online conversion, and how its premium price point holds against lower-cost alternatives as the ingredient attracts more entrants.

Featured on @cpglatest: see the post

Sources

• Premium L-Ergothioneine Capsules - GeneIII
• About GeneIII | L-Ergothioneine Made In-House
• About GeneIII | L-Ergothioneine Made In-House